Neoadjuvant chemotherapy for osseous malignant fibrous histiocytoma of the extremity

Results in 18 cases and comparison with 112 contemporary osteosarcoma patients treated with the same chemotherapy regimen

G. Bacci, S. Ferrari, F. Bertoni, M. Mercuri, C. Forni, S. Sottili, A. Gasbarrini, A. Tienghi, M. Cesari, M. Campanacci

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Eighteen patients with high grade malignant fibrous histiocytoma (MFH) of bone and 112 patients with high grade osteosarcoma (OS) of the extremity were treated with neoadjuvant chemotherapy comprised of methotrexate, cisplatinum, doxorubicin and ifosfamide, For the 18 patients with MFH, surgery involved amputation in 2 cases and limb salvage in 16 (89%); the 112 osteosarcoma patients had amputation in 8 cases and limb salvage procedure in 104 cases (93%) The rate of good histologic response to preoperative chemotherapy (90% or more tumor necrosis) was significantly higher in patients with osteosarcoma than in patients with MFH (74% vs 28%; p <0.003), However, at a median follow-up of 38 months (range 25-61), the 3-year event-free survival (EFS) did not differ in the two groups (MFH 77.8%, OS 70.5%; p = ns), In patients with MFH, no local recurrences were registered, whereas in the osteosarcoma group there were G local relapses (5.%) The effectiveness of neoadjuvant chemotherapy in the treatment of osteosarcoma has been assessed during the last 15 years The results of the present study seem to indicate that, in spite of a usually poor histologic response to preoperative treatment, neoadjuvant chemotherapy is very effective also in MFH of bone.

Original languageEnglish
Pages (from-to)293-299
Number of pages7
JournalJournal of Chemotherapy
Volume9
Issue number4
Publication statusPublished - 1997

Fingerprint

Malignant Fibrous Histiocytoma
Osteosarcoma
Extremities
Drug Therapy
Limb Salvage
Amputation
Bone and Bones
Recurrence
Ifosfamide
Neoadjuvant Therapy
Methotrexate
Doxorubicin
Disease-Free Survival
Necrosis

Keywords

  • Malignant fibrous histiocytoma of bone
  • Neoadjuvant chemotherapy
  • Osteosarcoma high grade

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Microbiology (medical)

Cite this

Neoadjuvant chemotherapy for osseous malignant fibrous histiocytoma of the extremity : Results in 18 cases and comparison with 112 contemporary osteosarcoma patients treated with the same chemotherapy regimen. / Bacci, G.; Ferrari, S.; Bertoni, F.; Mercuri, M.; Forni, C.; Sottili, S.; Gasbarrini, A.; Tienghi, A.; Cesari, M.; Campanacci, M.

In: Journal of Chemotherapy, Vol. 9, No. 4, 1997, p. 293-299.

Research output: Contribution to journalArticle

@article{359226c1d35646dd94f68348829640dd,
title = "Neoadjuvant chemotherapy for osseous malignant fibrous histiocytoma of the extremity: Results in 18 cases and comparison with 112 contemporary osteosarcoma patients treated with the same chemotherapy regimen",
abstract = "Eighteen patients with high grade malignant fibrous histiocytoma (MFH) of bone and 112 patients with high grade osteosarcoma (OS) of the extremity were treated with neoadjuvant chemotherapy comprised of methotrexate, cisplatinum, doxorubicin and ifosfamide, For the 18 patients with MFH, surgery involved amputation in 2 cases and limb salvage in 16 (89{\%}); the 112 osteosarcoma patients had amputation in 8 cases and limb salvage procedure in 104 cases (93{\%}) The rate of good histologic response to preoperative chemotherapy (90{\%} or more tumor necrosis) was significantly higher in patients with osteosarcoma than in patients with MFH (74{\%} vs 28{\%}; p <0.003), However, at a median follow-up of 38 months (range 25-61), the 3-year event-free survival (EFS) did not differ in the two groups (MFH 77.8{\%}, OS 70.5{\%}; p = ns), In patients with MFH, no local recurrences were registered, whereas in the osteosarcoma group there were G local relapses (5.{\%}) The effectiveness of neoadjuvant chemotherapy in the treatment of osteosarcoma has been assessed during the last 15 years The results of the present study seem to indicate that, in spite of a usually poor histologic response to preoperative treatment, neoadjuvant chemotherapy is very effective also in MFH of bone.",
keywords = "Malignant fibrous histiocytoma of bone, Neoadjuvant chemotherapy, Osteosarcoma high grade",
author = "G. Bacci and S. Ferrari and F. Bertoni and M. Mercuri and C. Forni and S. Sottili and A. Gasbarrini and A. Tienghi and M. Cesari and M. Campanacci",
year = "1997",
language = "English",
volume = "9",
pages = "293--299",
journal = "Journal of Chemotherapy",
issn = "1120-009X",
publisher = "Maney Publishing",
number = "4",

}

TY - JOUR

T1 - Neoadjuvant chemotherapy for osseous malignant fibrous histiocytoma of the extremity

T2 - Results in 18 cases and comparison with 112 contemporary osteosarcoma patients treated with the same chemotherapy regimen

AU - Bacci, G.

AU - Ferrari, S.

AU - Bertoni, F.

AU - Mercuri, M.

AU - Forni, C.

AU - Sottili, S.

AU - Gasbarrini, A.

AU - Tienghi, A.

AU - Cesari, M.

AU - Campanacci, M.

PY - 1997

Y1 - 1997

N2 - Eighteen patients with high grade malignant fibrous histiocytoma (MFH) of bone and 112 patients with high grade osteosarcoma (OS) of the extremity were treated with neoadjuvant chemotherapy comprised of methotrexate, cisplatinum, doxorubicin and ifosfamide, For the 18 patients with MFH, surgery involved amputation in 2 cases and limb salvage in 16 (89%); the 112 osteosarcoma patients had amputation in 8 cases and limb salvage procedure in 104 cases (93%) The rate of good histologic response to preoperative chemotherapy (90% or more tumor necrosis) was significantly higher in patients with osteosarcoma than in patients with MFH (74% vs 28%; p <0.003), However, at a median follow-up of 38 months (range 25-61), the 3-year event-free survival (EFS) did not differ in the two groups (MFH 77.8%, OS 70.5%; p = ns), In patients with MFH, no local recurrences were registered, whereas in the osteosarcoma group there were G local relapses (5.%) The effectiveness of neoadjuvant chemotherapy in the treatment of osteosarcoma has been assessed during the last 15 years The results of the present study seem to indicate that, in spite of a usually poor histologic response to preoperative treatment, neoadjuvant chemotherapy is very effective also in MFH of bone.

AB - Eighteen patients with high grade malignant fibrous histiocytoma (MFH) of bone and 112 patients with high grade osteosarcoma (OS) of the extremity were treated with neoadjuvant chemotherapy comprised of methotrexate, cisplatinum, doxorubicin and ifosfamide, For the 18 patients with MFH, surgery involved amputation in 2 cases and limb salvage in 16 (89%); the 112 osteosarcoma patients had amputation in 8 cases and limb salvage procedure in 104 cases (93%) The rate of good histologic response to preoperative chemotherapy (90% or more tumor necrosis) was significantly higher in patients with osteosarcoma than in patients with MFH (74% vs 28%; p <0.003), However, at a median follow-up of 38 months (range 25-61), the 3-year event-free survival (EFS) did not differ in the two groups (MFH 77.8%, OS 70.5%; p = ns), In patients with MFH, no local recurrences were registered, whereas in the osteosarcoma group there were G local relapses (5.%) The effectiveness of neoadjuvant chemotherapy in the treatment of osteosarcoma has been assessed during the last 15 years The results of the present study seem to indicate that, in spite of a usually poor histologic response to preoperative treatment, neoadjuvant chemotherapy is very effective also in MFH of bone.

KW - Malignant fibrous histiocytoma of bone

KW - Neoadjuvant chemotherapy

KW - Osteosarcoma high grade

UR - http://www.scopus.com/inward/record.url?scp=8544219677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8544219677&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 293

EP - 299

JO - Journal of Chemotherapy

JF - Journal of Chemotherapy

SN - 1120-009X

IS - 4

ER -